Ritlecitinib
| CAS No. | 1792180-81-4 |
|---|---|
| MDL No. | N/A |
| MF | C15H19N5O |
| MW | 285.34 |
| InChI Key | CBRJPFGIXUFMTM-WDEREUQCSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Ritlecitinib is a pyrrolopyrimidine with a 7H-pyrrolo[2,3-d]pyrimidine core substituted at position 4 by a [(3R,6S)-6-methyl-1-(prop-2-enoyl)piperidin-3-yl]amino group. It is a dual inhibitor of Janus kinase 3 and the TEC family of tyrosine kinases. It functions as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an antirheumatic, anti-inflammatory, immunosuppressive, and dermatologic drug. It is classified as a pyrrolopyrimidine, N-acylpiperidine, secondary amino compound, member of acrylamides, and tertiary carboxamide. It is the conjugate base of ritlecitinib(1+).
| CAS No. | 1792180-81-4 |
|---|---|
| Product Name | Ritlecitinib |
Biological Targets
ITK·BMX·TEC·TXK·BTK·
Associated Conditions
mycosis fungoides·Crohn's disease·Vitiligo·alopecia areata·kidney disease·
* The information provided here is compiled from public sources and is for reference only.
